-=Recro Pharma (REPH) reported earnings on Mon 11 May 20 (b/o)

Recro Pharma (NASDAQ:REPH): Q1 GAAP EPS of -$0.33 misses by $0.30.

Revenue of $21.78M (-13.1% Y/Y) beats by $2.33M.

Net loss: ($7.7M); loss/share: ($0.33).

Non-GAAP EBITDA: $2.7M.

2020 guidance: Revenue: $80M - 85M from $97M - 100M; non-GAAP EBITDA: $26M - 30M (standalone).

Recro Pharma Inc is a contract development and manufacturing company. The company is engaged in the development, formulation, regulatory support, manufacturing, and packaging of oral solid dose drug products. Its product portfolio includes Ritalin LA; Focalin XR; Verelan PM, SR and Verapamil PM; Verapamil SR and Zohydro ER.